Literature DB >> 17287312

Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays.

Shannon L Harris1, How Tsao, Lindsey Ashton, David Goldblatt, Philip Fernsten.   

Abstract

Antibody avidity, the strength of the multivalent interaction between antibodies and their antigens, is an important characteristic of protective immune responses. We have developed an inhibition enzyme-linked immunosorbent assay (ELISA) to measure antibody avidity for the capsular polysaccharide (PS) of Neisseria meningitidis group C (MnC) and determined the avidity constants (K(D)s) for 100 sera from children immunized with an MnC PS conjugate vaccine. The avidity constants were compared to the avidity indices (AI) obtained for the same sera using a chaotropic ELISA protocol. After the primary immunization series, the geometric mean (GM) K(D) was 674 nM and did not change in the months following immunization. However, the GM avidity did increase after the booster dose (GM K(D), 414 nM 1 month after booster immunization). In contrast, the GM AI increased from an initial value of 118 after the primary immunization series to 147 6 months after the completion of the primary immunization series and then further increased to 178 after booster immunization. At the individual subject level, the avidity constant and AI correlated after the primary immunization series and after booster immunization but not prior to boosting. This work suggests that the AI, as measured by the chaotropic ELISA, in contrast to the K(D), reflects changes that render antibody populations less susceptible to disruption by chaotropic agents without directly affecting the strength of the binding interactions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287312      PMCID: PMC1865604          DOI: 10.1128/CVI.00241-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  32 in total

1.  Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae.

Authors:  M Anttila; M Voutilainen; V Jäntti; J Eskola; H Käyhty
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide.

Authors:  Peter C Giardina; Emma Longworth; Renee E Evans-Johnson; Michaelene L Bessette; Hong Zhang; Ray Borrow; Dace Madore; Philip Fernsten
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

3.  Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children.

Authors:  Dan M Granoff; Amy Morgan; Jo Anne Welsch
Journal:  Vaccine       Date:  2005-07-29       Impact factor: 3.641

4.  Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults.

Authors:  P Richmond; D Goldblatt; P C Fusco; J D Fusco; I Heron; S Clark; R Borrow; F Michon
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

5.  Avidity determinations for Haemophilus influenzae Type b anti-polyribosylribitol phosphate antibodies.

Authors:  Sandra Romero-Steiner; Patricia F Holder; Patricia Gomez de Leon; Willie Spear; Thomas W Hennessy; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

6.  Artifacts with the thiocyanate elution method for estimating relative antibody avidity.

Authors:  B M Gray; D R Shaw
Journal:  J Immunol Methods       Date:  1993-01-04       Impact factor: 2.303

7.  Carbohydrate-enzyme conjugates for competitive EIA.

Authors:  E Vorberg; D R Bundle
Journal:  J Immunol Methods       Date:  1990-08-28       Impact factor: 2.303

8.  O-antigen biotin conjugates. Preparation and use in direct competitive enzyme immunoassays.

Authors:  P J Meikle; N M Young; D R Bundle
Journal:  J Immunol Methods       Date:  1990-09-14       Impact factor: 2.303

9.  Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.

Authors:  Jo Southern; Sarah Deane; Lindsey Ashton; Ray Borrow; David Goldblatt; Nick Andrews; Paul Balmer; Rhonwen Morris; J Simon Kroll; Elizabeth Miller
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

10.  Murine immune response to Neisseria meningitidis group C capsular polysaccharide: analysis of monoclonal antibodies generated in response to a thymus-independent antigen and a thymus-dependent toxoid conjugate vaccine.

Authors:  P A García-Ojeda; M E Monser; L J Rubinstein; H J Jennings; K E Stein
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

View more
  8 in total

1.  Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients.

Authors:  A Meerveld-Eggink; O de Weerdt; R M de Voer; G A M Berbers; H van Velzen-Blad; B J Vlaminckx; D H Biesma; G T Rijkers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-24       Impact factor: 3.267

2.  Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Troy J Kemp; Carolina Porras; Ligia A Pinto
Journal:  Mol Cell Probes       Date:  2012-01-18       Impact factor: 2.365

3.  Thermodynamics and density of binding of a panel of antibodies to high-molecular-weight capsular polysaccharides.

Authors:  Shannon L Harris; Philip Fernsten
Journal:  Clin Vaccine Immunol       Date:  2008-11-12

4.  Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes.

Authors:  Ashley L St John; Cheryl Y Chan; Herman F Staats; Kam W Leong; Soman N Abraham
Journal:  Nat Mater       Date:  2012-01-22       Impact factor: 43.841

5.  Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14.

Authors:  Dodi Safari; Huberta A T Dekker; John A F Joosten; Dirk Michalik; Adriana Carvalho de Souza; Roberto Adamo; Martina Lahmann; Andreas Sundgren; Stefan Oscarson; Johannis P Kamerling; Harm Snippe
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

6.  Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis.

Authors:  Kenneth Smith; Jennifer J Muther; Angie L Duke; Emily McKee; Nai-Ying Zheng; Patrick C Wilson; Judith A James
Journal:  Immunobiology       Date:  2012-09-03       Impact factor: 3.144

7.  Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers.

Authors:  Susanne P Stoof; Fiona R M van der Klis; Debbie M van Rooijen; Mirjam J Knol; Elisabeth A M Sanders; Guy A M Berbers
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

8.  Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates.

Authors:  Risini D Weeratna; Ghania Chikh; Lu Zhang; James D Fraser; Jennifer M Thorn; James R Merson; Michael J McCluskie; Brian R Champion; Heather L Davis
Journal:  Immun Inflamm Dis       Date:  2016-04-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.